Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Hamm

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
The Lancet. Oncology|October 8, 2013
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 studyAhmad Awada, Agustin A Garcia, Stephen Chan, et al.
Cancer Research Communications|January 27, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients With Select Solid TumorsJong Chul Park, David Berz, Manish R Sharma, et al.
Cancer Research Communications|February 22, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid TumorsJong Chul Park, David Berz, Manish R Sharma, et al.
Breast Cancer Research and Treatment|February 3, 2022
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancerPatricia A Ganz, Hanna Bandos, Charles E Geyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25B Fisher, S Anderson, A DeCillis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trialJ M Weiss, T Csoszi, M Maglakelidze, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
The Lancet. Oncology|October 8, 2013
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 studyAhmad Awada, Agustin A Garcia, Stephen Chan, et al.
Cancer Research Communications|January 27, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients With Select Solid TumorsJong Chul Park, David Berz, Manish R Sharma, et al.
Cancer Research Communications|February 22, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid TumorsJong Chul Park, David Berz, Manish R Sharma, et al.
Breast Cancer Research and Treatment|February 3, 2022
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancerPatricia A Ganz, Hanna Bandos, Charles E Geyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25B Fisher, S Anderson, A DeCillis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trialJ M Weiss, T Csoszi, M Maglakelidze, et al.
Pageof 5